Caplacizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Caplacizumab
Accession Number
DB06081
Type
Small Molecule
Groups
Investigational
Description

ALX-0081 is a novel ‘first-in-class’ therapeutic Nanobody® targeting von Willebrand Factor (vWF), which can reduce the risk of thrombosis in patients with acute coronary syndrome. ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Synonyms
Not Available
External IDs
ALX-0081
Categories
UNII
2R27AB6766
CAS number
915810-67-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in cardiovascular disorders and thrombosis.

Pharmacodynamics

ALX-0081 is intended to prevent arterial thrombosis, without interfering with the desired haemostatis (wound healing) in the patient which results in less bleeding complications.

Mechanism of action

ALX-0081 is a Nanobody® targeted against von Willebrand Factor (vWF), a protein found in the blood, that acts at a very early stage in the coagulation cascade, namely platelet adhesion, in contrast to currently available anti-platelet drugs which work only in the late stage of platelet aggregation. The addition of ALX-0081 to the range of tools currently employed in an anti-thrombotic regimen may, therefore, have the potential to improve the overall efficacy of anti-platelet aggregation therapy and lead to an increased use of anti-thrombotic treatment in clinical indications like ACS where there is a high need for immediate and safe therapy.

TargetActionsOrganism
Uvon Willebrand factorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Caplacizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Caplacizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Caplacizumab.
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Caplacizumab.
AncrodCaplacizumab may increase the anticoagulant activities of Ancrod.
AndrographolideAndrographolide may increase the anticoagulant activities of Caplacizumab.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Caplacizumab.
Antithrombin III humanCaplacizumab may increase the anticoagulant activities of Antithrombin III human.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab.
ApixabanCaplacizumab may increase the anticoagulant activities of Apixaban.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Caplacizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentNon ST Segment Elevation Myocardial Infarction (NSTEMI) / Stable Angina (Associated With High Risk PCI) / Unstable Angina (UA)1
3Active Not RecruitingTreatmentAcquired Thrombotic Thrombocytopenic Purpura1
3CompletedTreatmentAcquired Thrombotic Thrombocytopenic Purpura1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein n-terminus binding
Specific Function
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surf...
Gene Name
VWF
Uniprot ID
P04275
Uniprot Name
von Willebrand factor
Molecular Weight
309261.83 Da

Drug created on November 18, 2007 11:29 / Updated on October 01, 2018 14:05